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Background
Williams-Beuren Syndrome (WBS) aris-
es when there is a genomic microdeletion
at human chromosome 7q11.23 (Mouse
5G2), resulting in various cardiovascular,
developmental, metabolic, and mental
disorders [1]. Cardiovascular complica-
tions from WBS are a frequent cause of
death. The deleted region is predisposed
to non-allelic homologous recombination
(NAHR) due to the presence of repetitive
DNA regions called segmental duplica-
tions. WBS can result in deletions of up to
1.83 Mb in a region containing roughly 28
genes that includes the gene ELN encoding
the tissue structural protein elastin [2].
Many of the cardiovascular features of
WBS can be partially explained by elastin
defects. WBS individuals have a combined
prevalence of cardiovascular disease of
84% that includes supra- and sub-aortic
stenosis (SVAS); aortic, pulmonary, and
mitral valvular disease; aortic coarctation;
hypertension; and, less commonly, myo-
cardial infarction [2,3]. These defects have
also been found in mouse models [4].
Elastin not only provides ‘‘elastic’’ support
for vessels, it also serves as a negative
regulator for smooth muscle cell prolifer-
ation. WBS patients are also at high risk
for hypertension and Eln
+/2 mice are
hypertensive [1,4]. In 2006, Del Campo
et al. recognized that hemizygosity of the
NCF1 gene as a result of the largest
recognized WBS microdeletion—about
1.83 Mb—decreases the risk for hyperten-
sion in WBS patients compared to those
possessing the more common smaller
deletion (1.55 Mb) not incorporating
NCF1 (Figure 1, top) [5]. NCF1 codes for
p47
phox, a critical subunit in the assembly
of NADPH oxidase (NOX); homozygous
deficiency accounts for 20% of patients
with chronic granulomatous disease, a
disorder associated with repeated infec-
tions due to an inability to kill bacteria.
p47
phox is a major effector of angiotensin II
(AngII), as demonstrated by a lack of
elevation in blood pressure of Ncf1
2/2
mice [6]. In this issue of PLoS Genetics,
Campuzano and colleagues replicate the
WBS cardiovascular phenotype in a WBS
mouse model with and without a deletion
of the Ncf1 gene [7]. Their study has broad
implications for our understanding of
hypertension- and reactive oxygen species
(ROS)-related cardiovascular disease.
A Genetic Basis for
Hypertension in WBS
The investigation of Campuzano et al.
[7] determined whether oxidative stress
is a feature of WBS mice and whether
genetic or pharmacologic reduction of
NOX activity reduces oxidative stress
and ameliorates hypertension associated
with these mice. Vascular NOX produc-
tion of superoxide has an important role in
various cardiovascular pathologies, includ-
ing hypertension. Superoxide antagonizes
the vasculo-protective molecule nitric ox-
ide (NO) either through direct interac-
tion with NO or through oxidation of
the endothelial NO-synthase (eNOS) en-
zyme co-factor tetrahydrobiopterin. Cam-
puzano et al. observed that WBS mice
called ‘‘DD’’, with a 0.67 Mb deletion
from Limk1 to Trim50 (that contains Eln),
manifest a cardiovascular phenotype
including hypertension with elevated an-
giotensinogen (Agt), renin (Ren), and angio-
tensin converting enzyme (Ace) mRNA
throughout life (Figure 1, bottom) [7].
Another WBS syndrome mouse called
‘‘PD’’ with a 0.45 Mb deletion from Gtf2i
to Limk1 (not containing Eln) is normoten-
sive (Figure 1, bottom) [4]. These data
suggest that in WBS the absence of the
elastin gene is necessary for hypertension.
However, the DD condition was reversed
when the mice were mated with Ncf1
+/2
mice, indicating that the presence of the
Ncf1 gene also contributes to the observed
hypertension. As predicted, AngII levels in
the DD/Ncf1
+/2 mice were reduced with
respect to the DD mice alone, but elevated
with respect to wild type mice. These
combined studies indicate that both the
Eln gene deletion and the Ncf1 gene
presence contribute to observed murine
hypertension. It is of note that vascular
pathologies such as supravalvular aortic
stenosis were also corrected in DD mice
partially depleted of the Ncf1 gene.
Role of ROS in Hypertension
In addition to elevated AngII levels, DD
mice have elevated protein nitrosylation
and superoxide anions as determined by
dihydroethidium fluorescence in the as-
cending aorta. In contrast, DD/Ncf1
+/2
mice have reduced ROS in their aorta.
These observations are consistent with
other rodent hypertensive phenotypes
[8,9]. The fact that genetic reduction of
ROS-producing mechanisms occurred
in the DD/Ncf1
+/2 mice suggested that
pharmacologic treatment to reduce ROS
may also be helpful in treating DD mouse
hypertension. Treatment of DD mice with
the broad antioxidant apocynin and lo-
sartan (an angiotensin receptor type 1
antagonist) independently lowered blood
pressure in DD mice and, together, their
effect was additive. Blood pressure control
was associated with reduced vessel ROS
and lowered plasma AngII levels. Further,
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gree of anatomical changes in cardiac
hypertrophy and vascular elastic fiber
fragmentation. These pharmacologic stud-
ies suggest an alternative approach to
treating the hypertensive phenotype in
WBS patients. Currently, the most com-
mon treatments for WBS-induced hyper-
tension are beta-blockers and calcium
channel blockers. Using the present WBS
mouse studies as an insight, the combined
use of a specific antioxidant with losartan
appears mechanistically more rational.
Use of Antioxidants in
Hypertension
The use of antioxidants for the treat-
ment of vascular oxidant stress associated
with cardiovascular disease has been
questioned after failed clinical trials using
non-specific antioxidants such as vitamins
C and E [10]. Recognizing specific
etiologies of superoxide in hypertension
suggests that past antioxidant clinical trials
were not well targeted to superoxide or
hydrogen peroxide. To date, ROS-specific
treatments such as the superoxide dismu-
tase mimetic tempol have not been used in
clinical trials. Tempol has been partially
successful in animal models to treat
hypertension [8,11,12]. When tempol is
tagged with a mitochondrial-specific tag,
the drug mitoTEMPO has been used to
successfully treat hypertension in two
rodent models [8,9]. Campuzano et al.
[7] also used the antioxidant apocynin to
treat hypertension and both pre- and post-
natal SVAS in the WBS mouse model.
Although the specificity of apocynin for
NOX is controversial, when it is delivered
clinically by inhalation, it lowers an
exhaled breath marker for ROS and
increases a nitric oxide marker [13,14].
ROS in Thrombosis
In addition to hypertension and devel-
opmental structural defects in the cardio-
vascular system, increased vascular ROS
may increase arterial thrombosis risk.
Several animal models have been associ-
ated with increased vascular ROS and
higher arterial thrombosis risk. Both heme
oxygenase I–deleted mice and prolylcar-
boxypeptidase-deficient mice have in-
creased vascular ROS and reduced arte-
rial thrombosis occlusion times [9,15].
Vascular ROS is associated with uncou-
pled eNOS, inactivated thrombomodulin,
and increased endothelial cell tissue factor
and plasminogen activator inhibitor 1
[9,16]. In the case of prolylcarboxypepti-
dase deficiency, in vivo treatment with
apocynin or tempol resulted in correction
of thrombosis risk and reduction in tissue
ROS. Myocardial infarction and stroke
are uncommon in WBS patients, probably
due to the overriding risk posed by their
severe cardiovascular developmental ab-
normalities. However, we would predict
that the DD mice would be prothrombotic
on ROS-generating thrombosis models,
and specific antioxidants to superoxide or
hydrogen peroxide would reduce any
Figure 1. Genotype and phenotype of human and murine Williams-Beuren Syndrome. Top: human WBS locus; Bottom: murine WBS locus;
Left: genotypes; Right: phenotypes. In the human WBS locus, deletion of ELN is associated with hypertension. WBS patients with deletions
incorporating loss of NCF1 (1.83 Mb) are at lower risk for hypertension compared to patients with the more common WBS deletion (1.55 Mb). In the
murine WBS locus, the DD mouse with a 0.67 Mb deletion containing Eln is hypertensive. It contains both Ncf1 alleles (dotted lines indicate that the
gene is present). Mice with an adjacent PD deletion are normotensive [4]. Hypertension in the DD mouse is corrected when mated with Ncf1
+/2 mice.
doi:10.1371/journal.pgen.1002479.g001
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ing hypertension.
Future Directions
The studies by Campuzano et al. [7] on
WBS show a double-hit genetic basis for
ROS- and hypertension-related cardiovas-
cular disease. They indicate that both
pharmacologic and genetic targets could
be used to manage the specific manifesta-
tions of WBS, and hypertension in gener-
al. Further, we believe that these ap-
proaches may also be useful in reducing
arterial thrombosis risk in susceptible
populations.
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